AngioDynamics (ANGO) Q3 2026 earnings review
Topline Momentum Intact, but Supply Chain Shocks Derail Cash Flow and Margins
AngioDynamics delivered a solid top-line beat in Q3, with pro forma net sales growing 8.9% YoY to $78.4M, driven by 19.0% growth in its strategic Med Tech portfolio. Management confidently raised full-year guidance for revenue, Med Tech growth, Adjusted EBITDA, and EPS. However, the operational reality beneath the revenue line is messy. Gross margin is decelerating, plunging to 52.9% from 56.4% last quarter due to tariffs and manufacturing transition costs. More critically, the cash flow trajectory is reversing. Sudden sterilization vendor shutdowns are forcing a $3-5M defensive inventory build in Q4, causing management to walk back their prior promise of full-year positive cash flow to 'slightly negative'.
🐂 Bull Case
The strategic pivot continues to pay off. All three major Med Tech platforms—Auryon, Mechanical Thrombectomy, and NanoKnife—posted high-teens to low-twenties YoY growth in Q3. This segment now commands strong market demand and supports the raised FY26 revenue guidance.
With the CPT 1 code for prostate procedures taking effect in January, NanoKnife adoption is accelerating. A 21% YoY revenue jump (driven by 20% probe growth and 25% capital growth) signals that the reimbursement tailwind is actively translating to hospital purchasing.
🐻 Bear Case
The company's plan to demonstrate a self-sustaining, cash-generative business model has been derailed. Unexpected sterilization facility shutdowns mean ANGO must burn $3-5M in Q4 to stockpile inventory, reversing the cash flow narrative into negative territory for the year.
Despite shifting mix to higher-margin Med Tech products, total gross margin fell 110 bps YoY to 52.9%. Tariffs ($1.3M in Q3), inflation, and Costa Rica manufacturing transition 'underabsorption' are eating the expected profitability gains.
⚖️ Verdict: ⚪
Neutral. The commercial execution in the Med Tech portfolio is genuinely excellent, warranting the guidance raises. However, the abrupt gross margin compression and sterilization supply chain issues reveal vulnerabilities in operations that make the bottom-line highly unpredictable.
Key Themes
Broad-Based Med Tech Acceleration
The Med Tech segment is accelerating as the undisputed growth engine, expanding 19.0% YoY to $37.3M. Execution is remarkably balanced across all pillars: Auryon atherectomy grew 17.9% to $16.3M, the Mechanical Thrombectomy portfolio (AlphaVac/AngioVac) grew 17.9% to $11.5M, and NanoKnife grew 21.0% to $7.6M. This diversified strength reduces reliance on any single product launch and validates the company's multi-year portfolio transformation.
Sterilization Shutdowns Force Cash Flow Reversal
A significant new operational risk emerged: sterilization vendors advised the company of temporary shutdowns for maintenance in Q4. To avoid commercial stockouts, AngioDynamics is forced into a defensive inventory build, accelerating $3.0M-$5.0M of cash use. This breaks the management's prior commitment to full-year positive cash flow, reversing the trend to 'slightly negative' for FY26.
Gross Margin Decelerating Despite Favorable Mix
A critical contradiction in the company's narrative is unfolding on the gross margin line. Despite Med Tech (which historically carries higher margins) growing significantly faster than Med Device, total gross margin compressed to 52.9% (down 110 bps YoY and 350 bps sequentially). Management cited the impact and timing of tariffs ($1.3M hit in Q3), inflation, and manufacturing transition costs. If mix shift can't outpace operational costs, long-term margin targets are at risk.
NanoKnife Prostate Reimbursement Catalyst
The CPT 1 code for prostate procedures became effective on January 1, 2026. The impact is already visible: NanoKnife probe sales surged 20.0% and capital sales jumped 24.9% YoY. This indicates that urologists and hospitals are actively upgrading equipment and increasing procedure volumes now that a clearer reimbursement pathway exists.
Med Device Segment Provides Stable Funding
While no longer the strategic focus, the legacy Med Device segment remains incredibly stable, posting 1.1% YoY growth to $41.1M. This segment acts as a crucial cash cow, funding the aggressive commercial investments and R&D required to support the higher-growth Med Tech platforms.
Other KPIs
Accelerating sequentially and YoY (up from $1.3M in 25Q3). Despite the gross margin pressures, disciplined operating expense control allowed the company to deliver positive Adjusted EBITDA, pushing the full-year guidance up to $10.0-$12.0M.
The company maintains a debt-free balance sheet. However, the cash balance has been steadily declining from $55.9M at the end of FY25, and with the forced inventory build coming in Q4, liquidity requires monitoring, though it remains sufficient for near-term operations.
Guidance
Accelerating. The guidance was raised from the prior $312-$314M range. The midpoint ($314.5M) implies approximately 7.4% YoY growth over FY25's pro forma $292.7M. It also implies a Q4 revenue of roughly $80.9M, indicating steady sequential momentum into the end of the year.
Accelerating. Raised from 14%-16%. Given YTD Med Tech sales of $108.2M, the company implies Q4 Med Tech sales of roughly $37.5M to $40.0M, showing deep confidence in the ongoing commercial traction of Auryon, AlphaVac, and NanoKnife.
Accelerating. Raised from $8.0-$10.0M. Management is extracting operating leverage from the top-line beat despite gross margin headwinds, demonstrating tighter control over SG&A.
Reversing. Downward revision from prior guidance of 'Positive'. Driven entirely by a defensive $3.0M to $5.0M working capital use to build inventory ahead of sterilization vendor maintenance shutdowns in Q4.
Key Questions
Sterilization Vendor Risk
How long are the temporary sterilization vendor shutdowns expected to last, and is there a risk of product stockouts spilling over into Q1 FY27 if the maintenance takes longer than planned?
Gross Margin Bridge
With the Costa Rica manufacturing transition savings seemingly being entirely absorbed by inflation and tariffs in H2, what is the realistic timeline and bridge to returning to the mid-50s or higher gross margin target in FY27?
NanoKnife Capital vs Disposable Mix
With NanoKnife capital sales growing 24.9% this quarter, what is the expected lag time before these new placements translate into consistent, recurring disposable probe revenue under the new CPT code?